The complication of diabetic neuropathy places the client at risk for which of these conditions?

Choice A rationale: Hyperosmolar hyperglycemic nonketotic syndrome (HHNS) is a serious complication of diabetes characterized by extremely high blood glucose levels, often over 600 mg/dL, and severe dehydration. The absence of ketones and acidosis, along with the presence of severe dehydration, hypokalemia, and elevated BUN, are hallmark signs. A fingerstick glucose of 1000 mg/dL is a key indicator of HHNS.
Choice B rationale: Diabetic ketoacidosis (DKA) is a life-threatening complication of diabetes characterized by hyperglycemia, ketosis, and metabolic acidosis. While the client has hyperglycemia, the absence of ketones and a normal pH rules out DKA. Ketones are a byproduct of fat metabolism, which occurs when the body lacks sufficient insulin to utilize glucose for energy.
Choice C rationale: Diabetic neuropathy is a long-term complication of diabetes resulting from nerve damage due to prolonged hyperglycemia. It can manifest as numbness, tingling, or pain, particularly in the extremities. The client's acute symptoms of dehydration, polyphagia, and extremely high blood glucose are indicative of an acute metabolic crisis, not a chronic neurological condition.
Choice D rationale: Hypoglycemia is a condition characterized by abnormally low blood glucose levels, typically below 70 mg/dL. The client’s fingerstick glucose of 1000 mg/dL is a sign of severe hyperglycemia, the opposite of hypoglycemia. Symptoms of hypoglycemia include shakiness, dizziness, and confusion, but not severe dehydration or polyphagia.

Choice A rationale: Basal dosing involves a continuous, low-level release of insulin throughout the day and night to mimic the pancreas's natural basal insulin secretion. This helps to maintain stable blood glucose levels between meals and overnight, preventing hyperglycemia. Long-acting insulins like glargine or detemir are used for this purpose.
Choice B rationale: This statement describes bolus or prandial insulin dosing, not basal dosing. Bolus insulin is administered before meals to manage the anticipated rise in blood glucose from food intake. Basal insulin provides a constant background level and does not correlate with specific meals.
Choice C rationale: Glargine is a long-acting basal insulin. It is designed to be given once or twice a day to provide a steady, continuous insulin level. Bolus insulin, such as lispro or aspart, is given with meals to cover the carbohydrate intake. Glargine should never be used as a bolus with meals due to its delayed onset and peakless profile.
Choice D rationale: Basal-bolus dosing is the modern, intensive method of managing blood glucose, not the traditional one. The traditional approach often involved fixed-dose insulin regimens. Basal-bolus therapy, which combines long-acting basal insulin with short-acting bolus insulin, is a more flexible and effective approach that more closely mimics normal pancreatic function.